Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a brain protein predict stroke recovery?

NCT ID NCT02860260

Knowledge-focused Sponsor: Centre Hospitalier Universitaire Dijon Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study measured levels of a brain protein called BDNF in 50 stroke patients who received a clot-busting drug. Researchers wanted to see if BDNF levels rise after treatment and if they could help predict recovery of movement, thinking, and mood three months later. The goal is to find an early marker that guides stroke care.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
rt-PA (a clot-busting drug)
What this could lead to
If successful, this could point toward using BDNF as an early marker to predict recovery after a stroke.
What could go wrong
This is a small, completed observational study with only 50 participants. It does not test a new treatment, so results may not lead to direct patient benefits.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

50 people

The number who actually took part.

Start date

Feb 2011

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients (or their person of trust in cases of inability) who have been informed about the research and given their consent to take part * Patients aged 18 years or older * Patients who have suffered a de novo recent ischemic stroke \< 12 hours * Patients who had cerebral imaging (CT-Scan or MRI) * Ischemic stroke severity, measured by the National Institute of Health Stroke Score (NIHSS), between 4 and 20 Exclusion Criteria: Patients without national health insurance cover * Patients with a clinical history of stroke * Patients with cerebral or sub-arachnoid haemorrhage * Patients with a transient ischemic attack * Time of symptom onset unknown * Patients with severe aphasia at the time of the ischemic stroke defined by a sub-score for item 9 (best language) of the NIHSS ≥ 2 * Patients with dementia prior to the ischemic stroke * Patients with a significant loss of autonomy prior to the ischemic stroke, defined by a Rankin score ≥ 4 * Patients with aphasia before the ischemic stroke * Patients with a contra-indication for cerebral MRI * Pregnant or breast-feeding women * Adults under guardianship * Subjects in custody * Patients who do not speak French

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Ischemic stroke are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

ischemic stroke

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Ischemic stroke

Contacts and locations

Locations

  • Centre Hospitalier Universitaire

    Dijon, 21079, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.